A potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Hyunhee | - |
dc.contributor.author | Jeong, Kyeong-Hoon | - |
dc.contributor.author | Han, Hye Young | - |
dc.contributor.author | Son, Hyun Joo | - |
dc.contributor.author | Kim, Su Sung | - |
dc.contributor.author | Lee, Hyun Jung | - |
dc.contributor.author | Kim, Shinae | - |
dc.contributor.author | Sa, Joon Ho | - |
dc.contributor.author | Jun, Hee-Sook | - |
dc.contributor.author | Ryu, Je Ho | - |
dc.contributor.author | Choi, Cheol Soo | - |
dc.date.available | 2020-02-28T06:44:46Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-12-05 | - |
dc.identifier.issn | 0014-2999 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9787 | - |
dc.description.abstract | 11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta HSD1) has been targeted for new drugs to treat type 2 diabetes and metabolic syndrome. In this study, we determined whether the inhibition of 11 beta HSD1 with a new selective inhibitor, SKI2852, could improve lipid profiles, glucose levels, and insulin sensitivity in type 2 diabetic and obese conditions. SKI2852 showed a potent inhibition of cortisone to cortisol conversion for over 80% in both liver and adipose tissue ex vivo from orally administered C57BL/6 mice, and in vivo analysis results were consistent with this. Repeated oral administrations of SKI2852 in diet-induced obesity (DLO) and ob/ob mice revealed a partially beneficial effect of SKI2852 in improving levels of cholesterols, triglycerides, free fatty acids, postprandial glucose, and/or blood hemoglobinAic. SKI2852 significantly reduced body weight increase in ob/ob mice, and efficiently suppressed hepatic mRNA levels of gluconeogenic enzymes in DIO mice. Moreover, SKI2852 enhanced hepatic and whole body insulin sensitivities in hyperinsulinemic-euglycemic clamp experiment in DIO mice. In conclusion, these results indicate that selective and potent inhibition of 11 beta HSD1 by SKI2852, thus blockade of active glucocorticoid conversion, may improve many aspects of metabolic parameters in type 2 diabetes and metabolic diseases, mainly by inhibitions of hepatic gluconeogenesis and partial improvements of lipid profiles. Our study strongly support that SKI2852 may have a great potential as a novel candidate drug for the treatment of diabetes and metabolic diseases. (C) 2015 Elsevier B.V. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF PHARMACOLOGY | - |
dc.subject | ADIPOSE-TISSUE | - |
dc.subject | 11-BETA-HSD1 INHIBITORS | - |
dc.subject | INSULIN SENSITIVITY | - |
dc.subject | THERAPEUTIC TARGET | - |
dc.subject | CUSHINGS-SYNDROME | - |
dc.subject | VISCERAL OBESITY | - |
dc.subject | CORTISOL | - |
dc.subject | OVEREXPRESSION | - |
dc.subject | REGENERATION | - |
dc.subject | EXPRESSION | - |
dc.title | A potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000364842800016 | - |
dc.identifier.doi | 10.1016/j.ejphar.2015.10.042 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF PHARMACOLOGY, v.768, pp.139 - 148 | - |
dc.identifier.scopusid | 2-s2.0-84947549685 | - |
dc.citation.endPage | 148 | - |
dc.citation.startPage | 139 | - |
dc.citation.title | EUROPEAN JOURNAL OF PHARMACOLOGY | - |
dc.citation.volume | 768 | - |
dc.contributor.affiliatedAuthor | Oh, Hyunhee | - |
dc.contributor.affiliatedAuthor | Jeong, Kyeong-Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Su Sung | - |
dc.contributor.affiliatedAuthor | Jun, Hee-Sook | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Soo | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | 11 beta-hydroxysteroid dehydrogenase type 1 | - |
dc.subject.keywordAuthor | Inhibitor | - |
dc.subject.keywordAuthor | Type 2 diabetes | - |
dc.subject.keywordAuthor | Glucocorticoid | - |
dc.subject.keywordAuthor | Gluconeogenesis | - |
dc.subject.keywordAuthor | Insulin resistance | - |
dc.subject.keywordPlus | ADIPOSE-TISSUE | - |
dc.subject.keywordPlus | 11-BETA-HSD1 INHIBITORS | - |
dc.subject.keywordPlus | INSULIN SENSITIVITY | - |
dc.subject.keywordPlus | THERAPEUTIC TARGET | - |
dc.subject.keywordPlus | CUSHINGS-SYNDROME | - |
dc.subject.keywordPlus | VISCERAL OBESITY | - |
dc.subject.keywordPlus | CORTISOL | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | REGENERATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.